{"pub": "washingtontimes", "url": "https://washingtontimes.com/news/2019/oct/15/strong-3q-for-johnson-johnson-and-a-better-outlook", "downloaded_at": "2019-10-15 12:54:07.507008+00:00", "title": "Higher 3Q profit, improved outlook for Johnson & Johnson", "language": "en", "text": "NEW BRUNSWICK, N.J. (AP) - Johnson & Johnson\u2019s third-quarter profit jumped 23%, beating Wall Street forecasts, thanks to higher sales of its key medicines for cancer and immune disorders and an acquisition-related charge a year earlier.\n\nThe world\u2019s biggest maker of health care products also raised its financial forecast for the year, and its shares jumped more than 2% in premarket action.\n\nJ&J; on Tuesday reported net income of $4.83 billion, or $1.81 per share. That was up from $3.93 billion, or $1.44 per share, in 2018\u2019s third quarter, when the drugmaker took a $1.13 billion charge related to research programs acquired with its purchase of Alios BioPharma.\n\nEarnings, adjusted for one-time gains and costs, came to $2.12 per share, easily topping analysts\u2019 projections for $2, according to a survey of analysts by Zacks Investment Research.\n\nRevenue of $20.73 billion, up 2% from $20.35 billion a year ago, also beat forecasts.\n\nJ&J;\u2019s prescription drugs business boosted sales 5% to $10.88 billion, led by cancer drugs Darzalex and Imbruvica and by Simponi, Stelara and Tremfya, which treat immune system disorders such as psoriasis, rheumatoid arthritis and Crohn\u2019s disease.\n\nThe consumer products business, which makes Johnson\u2019s baby shampoo, Neutrogena and Aveeno skin care products and pain relievers Tylenol and Motrin, posted a 1.6% increase in sales, to $3.47 billion. The medical device and diagnostics business, once J&J;\u2019s biggest segment, saw sales drop 3% to $6.38 billion.\n\nThe New Brunswick, New Jersey company forecast 2019 per-share earnings of $8.62 to $8.67, after adjustments for one-time items, and revenue of between $81.8 billion and $82.3 billion. In July, the company forecast adjusted per-share earnings between $8.53 and $8.63, and revenue between $80.8 billion and $81.6 billion.\n\nDuring the third quarter, Johnson & Johnson received approval from the U.S. Food and Drug Administration for additional uses for four of its medicines: blood thinner Xarelto, Type 2 diabetes pill Invokana, prostate cancer drug Erleada and Darzalex, for treating blood cancer multiple myeloma. In the European Union, Stelara received approval for treating ulcerative colitis and cancer drug Imbruvica won approval for two more uses. J&J; also launched two new medical devices, a surgical stapler and a new version of its Attune knee replacement system.\n\nIn premarket trading, J&J; shares jumped $2.38, or 1.8%, to $133.10.\n\n_____\n\nFollow Linda A. Johnson at https://twitter.com/LindaJ_onPharma\n\n_____\n\nPortions of this story were generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research.\n\nSign up for Daily Newsletters Manage Newsletters\n\nCopyright \u00a9 2019 The Washington Times, LLC.", "description": "Johnson & Johnson's third-quarter profit jumped 23%, beating Wall Street forecasts, thanks to higher sales of its key medicines for cancer and immune disorders and an acquisition-related charge a year earlier.", "authors": ["The Washington Times Http", "Linda A. Johnson"], "top_image": "https://twt-thumbs.washtimes.com/media/image/2019/10/15/earns_johnson__johnson_97349_c0-125-3000-1875_s1200x700.jpg?5df86175492ddcdc04d9d2b6261257b2d49617ee", "published_at": "2019-10-15"}